Figure 6.

QD325 inhibits tumor growth of MIA PaCa-2 xenograft. A) QD325 treatment at 5 mg/kg inhibits growth of MIA PaCa-2 xenograft in NOD/SCID mice. MIA PaCa-2 engrafted mice were randomized into vehicle control (n=5) or QD325 treatment (n=5) group when tumor size reached 65 mm³. QD325 was given at 5 mg/kg five times a week until day 44. Three mice from each group were euthanized for tissue analysis. Two mice remained in each group after day 44 and QD325 dose was increased from 5 mg/kg to 20 mg/kg until day 67. B) Body weight of engrafted mice was not affected by QD325 treatment from 5 to 20 mg/kg. Error bars indicate mean ± SEM. C) Gemcitabine treatment at 15 mg/kg inhibits growth of MIA PaCa-2 xenograft in NOD/SCID mice. MIA PaCa-2 engrafted mice were randomized into vehicle control (n=4), gemcitabine treatment 1 (n=3), gemcitabine treatment 2 (n=4) groups when tumor size reached 75mm³. In treatment 1, gemcitabine was given at 15 mg/kg once a week for 48 days; in treatment 2, gemcitabine was given at 15 mg/kg twice a week for 15 days. Data points represent mean ± SEM. D) Body weight of engrafted mice is not affected by gemcitabine treatment in either dosing frequency. E) QD325 treatment at 5 mg/kg inhibits growth of MIA PaCa-2 xenograft in NOD/SCID mice. MIA PaCa-2 engrafted mice were randomized into vehicle control (n=4), gemcitabine treatment (n=3), QD325 treatment (n=3) and combination treatment groups (n=3) when tumor size reached 75mm³. QD325 was given at 5 mg/kg five times a week and gemcitabine was given at 15 mg/kg once a week. Data points represent mean ± SEM. F) Body weight of engrafted mice was not affected by gemcitabine or QD325 treatment.